Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 22;7(6):491-494.
doi: 10.1002/iju5.12787. eCollection 2024 Nov.

Prostate neuroendocrine carcinoma successfully treated with etoposide and cisplatin

Masanori Ishizaki  1 , Masaru Hasumi  1 , Kazumichi Muramatsu  1 , Nobuaki Shimizu  1
Affiliations

Prostate neuroendocrine carcinoma successfully treated with etoposide and cisplatin

Masanori Ishizaki et al. IJU Case Rep. .

Abstract

Introduction: The frequency of neuroendocrine carcinoma of the prostate is low, accounting for approximately 1%-5% of all prostate cancers. Herein, we report the case of a patient who was diagnosed with prostate neuroendocrine carcinoma and successfully treated with etoposide and cisplatin.

Case presentation: A 74-year-old man presented to the urology department with the chief complaint of urinary retention. After a thorough examination, he was diagnosed with neuroendocrine carcinoma of the prostate and treated with etoposide and cisplatin, called "EP therapy." The patient remained in remission 1 year later.

Conclusion: A patient with neuroendocrine carcinoma of the prostate was successfully treated with etoposide and cisplatin, and the patient remained in remission. Prostate neuroendocrine carcinomas are rare and have poor prognoses. Therefore, information regarding treatments that can improve prognosis is needed.

Keywords: cisplatin; etoposide; metastasis; neuroendocrine carcinoma; prostate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
(1‐1) Initial MRI reveals an irregular mass occupying the pelvis, which appears to be primary prostate cancer. The image shows initial evidence of invasion into the surrounding tissues and multiple distant metastases. Arrows indicate pancreatic metastases. (1‐2) MRI after one course of treatment reveals a prominent reduction in tumor size and a trend toward improvement in invasion into the surrounding tissues. (1‐3) MRI after five courses reveals that most of the initial imaging findings have disappeared, including the primary tumor and distant metastases. (1‐4) MRI 1 year after the initial diagnosis. The initial imaging findings are absent.
Fig. 2
Fig. 2
Pathological findings are positive for chromogranin A, synaptophysin, and CD56, which are tumor markers of neuroendocrine carcinoma. (2‐1) chromogranin A. (2‐2) synaptophysin. (2‐3) CD56.
Fig. 3
Fig. 3
Clinical course and changes in PSA, NSE, and proGRP during the first year of treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Matei DV, Renne G, Pimentel M et al. Neuroendocrine differentiation in castration‐resistant prostate cancer: a systematic diagnostic attempt. Clin. Genitourin. Cancer 2012; 10: 164–173. - PubMed
    1. Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am. J. Surg. Pathol. 2006; 30: 684–693. - PubMed
    1. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992; 70: 254–268. - PubMed
    1. Abbas F, Civantos F, Benedetto P, Soloway MS. Small cell carcinoma of the bladder and prostate. Urology 1995; 46: 617–630. - PubMed
    1. Spiess PE, Pettaway CA, Vakar‐Lopez F et al. Treatment outcomes of small cell carcinoma of the prostate: a single‐center study. Cancer 2007; 110: 1729–1737. - PubMed

LinkOut - more resources